Abbott FreeStyle Libre 3 Plus Sensor (Recalled Models 78768-01 / 78769-01)

This entry isn't a normal product review so much as a safety assessment. The FreeStyle Libre 3 Plus is a real-time continuous glucose monitor indicated for people with diabetes aged four and older, and it is designed to stand in for routine fingerstick testing — a genuinely life-changing proposition for anyone managing insulin day to day. But the units covered here, model numbers 78768-01 and 78769-01, are the subject of an Abbott recall that the FDA has classified as Class I, its most serious category, meaning continued use may cause serious injury or death.

The problem is the worst kind a CGM can have: the affected sensors may report glucose levels that are falsely low. A user who trusts that reading may withhold insulin, over-treat a hypo that isn't happening, or miss a real high entirely. As of the January 7, 2026 figures, Abbott had reported 860 serious injuries and seven deaths linked to the issue, with 124 additional adverse events logged since the FDA's December 2025 early alert and no further deaths reported after November 14, 2025 (none of the deaths occurred in the US). Abbott has attributed the recall to a manufacturing issue, and roughly 3 million sensors are reported to have been distributed in the US.

If you wear a Libre 3 or Libre 3 Plus, the practical step is simple: check your sensor serial number at FreeStyleCheck.com. If it's affected, stop using it immediately, dispose of it and request a free replacement from Abbott. Readers and mobile apps are not affected, and other products in the family — FreeStyle Libre 14 day, Libre 2, Libre 2 Plus and Libre Pro — along with Abbott's other biowearables are not part of this action.

Judged as a product you might buy and wear today, the recalled sensor models cannot be recommended at any price. A glucose monitor's entire value proposition is that you can act on its numbers without second-guessing them; a device that may under-report your glucose is worse than no device at all, because it invites a confident wrong decision. The Class I designation is the regulator's way of saying exactly that, and the injury and fatality counts attached to this recall make the severity concrete rather than theoretical.

Abbott's response has been reasonably orderly — customer, distributor and provider letters went out on November 24, 2025, a serial-number lookup tool is live, replacements are free, and the recall notice was subsequently updated with a clarified lot list and revised reason for the recall. That's the right shape of remediation, and it's worth acknowledging. It is undercut, though, by what came after: roughly two weeks past the January 2026 figures, the FDA issued Abbott a warning letter citing quality system violations at its Alameda, California facility, including releasing finished FreeStyle Libre CGM devices without post-assembly accuracy testing. That reframes this from a one-off defect into a question about process control, and it's fair for buyers to weigh that when choosing a CGM platform.

One genuinely useful piece of guidance for current users: if a sensor reading doesn't match how you feel or what you'd expect, confirm with a blood glucose meter — either a standalone meter or the one built into the FreeStyle Libre 3 Reader — before making a treatment decision. That habit is good practice with any CGM and essential while this recall is being worked through.

A note on scope: we're assessing the recalled sensors and the recall response, not the accuracy, wear comfort, battery life or app experience of unaffected Libre 3 Plus stock, on which we have no data here. The rating reflects the safety picture for the specific models listed, and should not be read as a verdict on the wider Libre line, which is explicitly outside this recall.